论文部分内容阅读
目的 研究血管内皮生长因子 (vascularendothelialgrowthfactor,VEGF)在肝细胞癌(HCC)患者周围血血清中的表达水平与肝癌临床病理特征及肝癌转移复发之间的关系。方法 运用sandwich酶联免疫吸附测定法定量检测 115例HCC、40例肝脏良性疾病患者和 30例健康人血清中VEGF的含量。结果 HCC组血清VEGF表达水平 [(4 6 5 .6 2± 336 .2 4)pg/ml]与肝脏良性疾病组[(15 9.5 4± 12 0 .5 8)pg/ml]、与健康人组 [(12 3.5 3± 5 1.84)pg/ml]比较 ,差异均有显著性 (P值均 =0 .0 0 0 1) ;VEGF表达阳性率分别为 77.4%、2 5 0 %和 3.3%。HCC转移组患者血清VEGF表达水平与未转移组相比 ,差异有显著性 (P =0 .0 0 1)。血清VEGF表达水平还与HCC合并门静脉瘤栓、肿瘤大小和TNM分期密切相关 ,VEGF含量随TNM分期升高而逐步升高。结论 疗前HCC患者的血清VEGF表达水平 ,是反映HCC侵袭生长及转移潜能的有效生物学指标。
Objective To study the relationship between the expression of vascular endothelial growth factor (VEGF) in peripheral blood serum of patients with hepatocellular carcinoma (HCC) and the clinicopathological features of liver cancer and metastasis and recurrence of hepatocellular carcinoma. Methods Serum VEGF levels in 115 patients with HCC, 40 patients with benign liver diseases, and 30 healthy controls were detected quantitatively using sandwich enzyme-linked immunosorbent assay. Results Serum VEGF expression level in HCC group [(4 6 5 .62 ± 334.64) pg/ml] and liver benign disease group [(15 9.5 4 ± 12 0 .58) pg/ml], and healthy subjects There was a significant difference in the group [(12 3.5 3 ± 5 1.84) pg/ml] (P = 0.010); the positive rate of VEGF expression was 77.4%, 25%, and 3.3%, respectively. . The difference in serum VEGF expression between the HCC metastatic group and the non-metastatic group was statistically significant (P = 0.010). The level of serum VEGF was also closely related to HCC combined with portal vein tumor thrombus, tumor size and TNM stage, and VEGF level gradually increased with the increase of TNM stage. Conclusion The serum VEGF expression level in HCC patients before treatment is an effective biological indicator reflecting the invasion and metastatic potential of HCC.